We wanted to share Minoryx’s recent press release ‘Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX’.
We are pleased to share with you a promising update from Minoryx’s CALYX programme to treat adult cALD using Leriglitazone (MIN-102). Minoryx are currently conducting an extensive pre-screening campaign to identify eligible adults with cALD to take part in phase 3 of their clinical trial. The findings from the trials will enable Minoryx to take the final steps towards US approval of leriglitazone for treatment of ALD patients. Although we understand this announcment only applies to those living in the US, it is a positive step towards a treatment being available. We hope that once treatment is approved in the US that steps will be taken for EMA and NICE approval which will allow it to be available in the UK.
To read the press release: Minoryx cALD CALYX
If you would like any further information about the study, please visit www.cald-study.com